## Nagi G Ayad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6342982/publications.pdf Version: 2024-02-01



NACL C AVAD

#	Article	IF	CITATIONS
1	BET protein inhibition promotes non-myeloid cell mediated neuroprotection after rodent spinal cord contusion. Experimental Neurology, 2022, 352, 114035.	4.1	2
2	A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines. Neuro-Oncology Advances, 2022, 4, vdab192.	0.7	0
3	Organoid Models of Glioblastoma and Their Role in Drug Discovery. Frontiers in Cellular Neuroscience, 2021, 15, 605255.	3.7	31
4	The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion. Scientific Reports, 2021, 11, 23370.	3.3	14
5	Epigenetic pathways and plasticity in brain tumors. Neurobiology of Disease, 2020, 145, 105060.	4.4	15
6	Neuroinflammation Treatment via Targeted Delivery of Nanoparticles. Frontiers in Cellular Neuroscience, 2020, 14, 576037.	3.7	27
7	Bromodomain Protein BRD4 Is Essential for Hair Cell Function and Survival. Frontiers in Cell and Developmental Biology, 2020, 8, 576654.	3.7	5
8	Time series modeling of cell cycle exit identifies Brd4 dependent regulation of cerebellar neurogenesis. Nature Communications, 2019, 10, 3028.	12.8	33
9	Prenatal arsenic exposure alters the placental expression of multiple epigenetic regulators in a sex-dependent manner. Environmental Health, 2019, 18, 18.	4.0	25
10	Sustainable data and metadata management at the BD2K-LINCS Data Coordination and Integration Center. Scientific Data, 2018, 5, 180117.	5.3	22
11	Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nature Communications, 2018, 9, 5315.	12.8	78
12	Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme. Frontiers in Oncology, 2018, 8, 521.	2.8	13
13	Drug Repositioning in Clioblastoma: A Pathway Perspective. Frontiers in Pharmacology, 2018, 9, 218.	3.5	78
14	Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Molecular Cancer, 2018, 17, 74.	19.2	213
15	Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury. Experimental Neurology, 2018, 309, 181-192.	4.1	40
16	A cell based screening approach for identifying protein degradation regulators. Cell Cycle, 2017, 16, 940-946.	2.6	0
17	Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations. ACS Omega, 2017, 2, 4760-4771.	3.5	32
18	Casein kinase signaling in axon regeneration. Neural Regeneration Research, 2016, 11, 210.	3.0	2

Nagi G Ayad

#	Article	IF	CITATIONS
19	Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. Scientific Reports, 2015, 5, 16924.	3.3	55
20	Screening of cell cycle fusion proteins to identify kinase signaling networks. Cell Cycle, 2015, 14, 1274-1281.	2.6	1
21	Casein Kinase $\hat{l'}$ Is an APC/CCdh1 Substrate that Regulates Cerebellar Granule Cell Neurogenesis. Cell Reports, 2015, 11, 249-260.	6.4	30
22	The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8326-8331.	7.1	186
23	GSK3 inhibitors stabilize Wee1 and reduce cerebellar granule cell progenitor proliferation. Cell Cycle, 2015, 14, 417-424.	2.6	8
24	The APC/C and CK1 in the developing brain. Oncotarget, 2015, 6, 16792-16793.	1.8	0
25	ldentifying Glioblastoma Gene Networks Based on Hypergeometric Test Analysis. PLoS ONE, 2014, 9, e115842.	2.5	15
26	BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics, 2014, 9, 611-620.	2.7	123
27	Casein Kinase 1δ-dependent Wee1 Protein Degradation. Journal of Biological Chemistry, 2014, 289, 18893-18903.	3.4	22
28	The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers. Journal of Biological Chemistry, 2014, 289, 35494-35502.	3.4	102
29	Epigenetic pathways and glioblastoma treatment. Epigenetics, 2013, 8, 785-795.	2.7	54
30	Activation Domain-dependent Degradation of Somatic Wee1 Kinase. Journal of Biological Chemistry, 2010, 285, 6761-6769.	3.4	16
31	The Anaphase Promoting Complex Induces Substrate Degradation during Neuronal Differentiation. Journal of Biological Chemistry, 2009, 284, 4317-4323.	3.4	31
32	Redundant Ubiquitin Ligase Activities Regulate Wee1 Degradation and Mitotic Entry. Cell Cycle, 2007, 6, 2795-2799.	2.6	40
33	Identification of Ubiquitin Ligase Substrates by In Vitro Expression Cloning. Methods in Enzymology, 2005, 399, 404-414.	1.0	23
34	Tome-1, a Trigger of Mitotic Entry, Is Degraded during G1 via the APC. Cell, 2003, 113, 101-113.	28.9	164
35	Kinome-Wide Activity Classification of Small Molecules by Deep Learning. SSRN Electronic Journal, 0, ,	0.4	0